Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial.
about
Renin-angiotensin system blockade promotes a cardio-renal protection in albuminuric homozygous sickle cell patients.Nephrin as a biomarker of sickle cell glomerulopathy in Malawi.Clinical Features of β-Thalassemia and Sickle Cell Disease.Renal protection by atorvastatin in a murine model of sickle cell nephropathy.Prevalence of Microalbuminuria in Adult Patients with Sickle Cell Disease in Eastern Saudi Arabia.
P2860
Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial.
@en
Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial.
@nl
type
label
Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial.
@en
Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial.
@nl
prefLabel
Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial.
@en
Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial.
@nl
P2093
P2860
P50
P356
P1476
Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial
@en
P2093
Alecia C Nero
Alex George
Ashok B Raj
Catherine E Terrell
Courtney D Fitzhugh
Hans C Ackerman
Lisa McCord
Michael D Taylor
Prasad Bodas
Santosh L Saraf
P2860
P304
P356
10.1002/AJH.24810
P577
2017-07-19T00:00:00Z